NCT05295992

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

Daily Online Adaptive Radiation Therapy of Bladder Cancer for Reduction of Intestinal Toxicity: A Prospective Trial Using an Individualized Approach and Conventional Fractionation (ARTIA-Vesica)

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Varian, a Siemens Healthineers Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Conditions

• Muscle-Invasive Bladder Carcinoma

Interventions

Type	Name	Description
DEVICE	Varian Ethos Adaptive Radiation Therapy	Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Timeline

• Start date: 2022-03-15
• Primary completion: 2026-12-01
• Completion: 2027-03-01
• First posted: 2022-03-25
• Last updated: 2026-03-06

Locations

1 site across 1 country: Denmark